On this page
CALM3
calmodulin 3
CALM3 encodes calmodulin, a calcium-sensing protein that regulates cardiac electrical activity and numerous cellular processes throughout the body. The CALM3 gene provides instructions for making calmodulin, a protein that binds calcium ions and controls many essential cellular functions.
CALM3 is located on the long (q) arm of chromosome 19, at band 19q13.32. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 19 in the library →Overview
The CALM3 gene encodes one of three genetically distinct calmodulin proteins that are functionally identical. Despite being produced from separate genes, these proteins share the same amino acid sequence and serve as universal calcium sensors within cells. When calcium levels rise inside a cell, calmodulin undergoes a structural change that allows it to bind and regulate over 300 different target proteins.
Calmodulin is particularly important in cardiac muscle cells, where it modulates the activity of ion channels that control the heart's electrical rhythm. The protein helps regulate calcium handling during each heartbeat, coordinating the precise timing of electrical signals that maintain normal cardiac function. Although all three calmodulin genes contribute equally to the total cellular pool of calmodulin protein, research has shown that pathogenic variants in any single calmodulin gene can cause severe cardiac arrhythmias.
CALM3 is located on chromosome 19 and produces a 149 amino acid protein with four calcium-binding domains. The gene is expressed in virtually all cell types, reflecting calmodulin's fundamental role in cellular signalling. Pathogenic variants in CALM3 follow an autosomal dominant inheritance pattern, meaning a single altered copy can cause disease. Recognition of CALM3's clinical significance has led to its inclusion in the American College of Medical Genetics and Genomics secondary findings recommendations, highlighting variants that have important health implications when discovered incidentally during genetic testing.
What the gene does
The calmodulin protein encoded by CALM3 functions as the cell's primary calcium sensor, translating fluctuations in intracellular calcium concentration into specific cellular responses. In its calcium-free state, calmodulin adopts a relatively extended conformation. When calcium ions bind to the protein's EF-hand motifs, calmodulin undergoes a dramatic conformational change that exposes hydrophobic surfaces, enabling it to wrap around target proteins and modulate their activity.
In cardiac myocytes, calmodulin regulates multiple ion channels and transporters essential for normal electrical activity. The protein directly interacts with voltage-gated calcium channels, helping to control calcium influx during action potentials. Calmodulin also modulates potassium channels responsible for cardiac repolarisation, the process by which heart cells return to their resting electrical state after each contraction. This dual regulation of calcium entry and potassium efflux is crucial for maintaining appropriate action potential duration.
Beyond ion channel regulation, calmodulin activates numerous enzymes when bound to calcium. The protein stimulates calcium/calmodulin-dependent protein kinases, which phosphorylate target proteins to alter their function. Calmodulin also activates phosphodiesterases that break down cyclic nucleotide second messengers, modulating cellular responses to hormones and neurotransmitters. In smooth muscle cells, the calcium-calmodulin complex activates myosin light chain kinase, triggering muscle contraction.
The protein plays additional roles in cellular metabolism and gene expression. Calmodulin regulates nitric oxide synthase enzymes that produce the signalling molecule nitric oxide, which controls blood vessel tone and numerous other physiological processes. The protein also influences the activity of transcription factors, allowing calcium signals to directly affect which genes are switched on or off. Through these diverse interactions, calmodulin coordinates cellular responses to extracellular signals, integrating calcium signalling with metabolic state, gene expression, and cellular architecture.
Video: Genetics 101
Chromosome location
CALM3 is located on the long arm of chromosome 19 at position 13.32 (19q13.32). The gene spans a relatively compact genomic region, reflecting its ancient evolutionary origin and high degree of conservation across species. CALM3 contains six exons that encode the 149 amino acid calmodulin protein.
The chromosomal position of CALM3 places it in a gene-dense region of chromosome 19, which contains numerous genes involved in fundamental cellular processes. Interestingly, the human genome contains three separate calmodulin genes - CALM1, CALM2, and CALM3 - located on different chromosomes. This genetic redundancy likely reflects the critical importance of maintaining adequate calmodulin levels for cell survival. The three genes are not the result of recent duplication; rather, they have been maintained as separate loci throughout vertebrate evolution.
Despite their different genomic locations and distinct gene structures, all three calmodulin genes produce proteins with identical amino acid sequences. This unusual arrangement ensures robust calmodulin expression even if one gene is damaged, though pathogenic variants that alter the protein sequence can cause disease regardless of which gene is affected. The compact structure of CALM3, with relatively short introns and a small number of exons, may facilitate high-level constitutive expression in all cell types.
Protein structure
The calmodulin protein consists of 149 amino acids organised into a distinctive structure featuring four calcium-binding motifs known as EF-hands. The protein adopts a dumbbell shape, with two globular domains connected by a central flexible linker region. Each globular domain contains a pair of EF-hand motifs that cooperate to bind calcium ions.
EF-hand 1 (spanning amino acids 8-43) and EF-hand 2 (amino acids 44-79) form the N-terminal calcium-binding domain. Similarly, EF-hand 3 (amino acids 81-116) and EF-hand 4 (amino acids 117-149) comprise the C-terminal domain. Each EF-hand consists of a helix-loop-helix structure, where the loop region coordinates a single calcium ion through oxygen atoms from conserved acidic residues. The binding of calcium to these sites triggers conformational changes that expose hydrophobic patches on the protein surface.
The central flexible linker connecting the two globular domains allows calmodulin to adopt different conformations depending on its calcium occupancy and binding partners. When calcium is bound, the protein can wrap around target proteins, with the two domains clasping the target sequence from opposite sides. This conformational flexibility enables calmodulin to interact with a remarkably diverse array of target proteins that share little primary sequence similarity.
A region spanning amino acids 77-149 has been identified as necessary and sufficient for interaction with PCP4 (Purkinje cell protein 4), demonstrating how specific portions of calmodulin mediate distinct protein-protein interactions. The four EF-hands do not all bind calcium with equal affinity; the C-terminal EF-hands typically bind calcium more tightly than the N-terminal pair, allowing calmodulin to respond to different ranges of calcium concentration. This differential affinity contributes to calmodulin's ability to decode complex patterns of calcium signals.
Key variants
Pathogenic variants in CALM3 predominantly affect the protein's calcium-binding properties or its ability to regulate cardiac ion channels. Most disease-causing changes are missense variants that substitute a single amino acid within or near the EF-hand calcium-binding motifs. These substitutions typically reduce calmodulin's affinity for calcium or alter how the protein interacts with ion channel targets in cardiac myocytes.
Because the three human calmodulin genes produce identical proteins, variants at equivalent positions in CALM1, CALM2, or CALM3 generally cause similar phenotypes. The severity of cardiac arrhythmias associated with CALM3 variants can vary considerably, likely depending on the specific amino acid change and its impact on protein function. Some variants produce calmodulin proteins that retain partial function, whilst others severely impair calcium binding or target protein regulation.
The pathogenic variants identified to date suggest that even subtle changes to calmodulin structure can have profound effects on cardiac electrophysiology. This reflects the protein's critical role in maintaining precise calcium and potassium channel kinetics during each cardiac cycle. The autosomal dominant inheritance pattern means that individuals with one pathogenic CALM3 variant produce a mixture of normal and abnormal calmodulin protein. This mixed population of normal and abnormal calmodulin appears sufficient to disrupt cardiac rhythm regulation, though severity varies among affected individuals.
Sample of pathogenic variants
9 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.281A>C | p.Asp94Ala | Pathogenic/Likely pathogenic | ★★☆☆ | Long QT syndrome 1 |
c.286G>C | p.Asp96His | Pathogenic/Likely pathogenic | ★★☆☆ | CALM3-related disorder |
c.421G>A | p.Glu141Lys | Pathogenic | ★★☆☆ | Long QT syndrome 1 |
c.390C>G | p.Asp130Glu | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
c.426T>G | p.Phe142Leu | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
A103V | - | Pathogenic | - | Ventricular tachycardia, catecholaminergic polymorphic 6 |
c.389A>G | p.Asp130Gly | Pathogenic | - | Long QT syndrome 16 |
c.395A>G | p.Asp132Gly | Likely pathogenic | ★☆☆☆ | not provided |
c.422A>G | p.Glu141Gly | Likely pathogenic | ★☆☆☆ | Long QT syndrome 1 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in CALM3 are associated with severe cardiac arrhythmia syndromes that present primarily in childhood or adolescence. These conditions result from abnormal cardiac electrical activity caused by defective calcium signalling and ion channel regulation. Affected individuals may experience life-threatening arrhythmias that can lead to sudden cardiac death if not identified and managed appropriately.
The cardiac phenotypes associated with CALM3 variants fall into two main categories: long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Both conditions involve defects in calcium signalling that disrupt cardiac electrical activity. However, they affect different channels and regulatory processes, have characteristic features on electrocardiogram, and exhibit distinct triggers. Long QT syndrome is characterised by prolonged ventricular repolarisation, which creates electrical instability and increases the risk of torsades de pointes, a dangerous arrhythmia. Catecholaminergic polymorphic ventricular tachycardia involves episodes of rapid, irregular heartbeat triggered by physical activity or emotional stress, resulting from abnormal calcium handling in cardiac muscle cells.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic CALM3 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the NHS Genomic Medicine Service, CALM3 features on two specialist cardiac gene panels that guide genetic testing for inherited arrhythmia syndromes. The gene holds green (high evidence) status on both the Catecholaminergic Polymorphic VT panel and the Long QT Syndrome panel, reflecting strong clinical and research evidence linking CALM3 variants to these conditions.
The inclusion of CALM3 on these panels means that NHS genetics laboratories routinely analyse this gene when investigating patients with unexplained cardiac arrhythmias or family histories suggestive of inherited heart rhythm disorders. Green classification indicates that variants in CALM3 have been robustly associated with the respective cardiac phenotypes through multiple studies and clinical observations. This evidence level supports the use of CALM3 genetic testing in diagnostic pathways for individuals presenting with appropriate clinical features.
CALM3 is also included in the American College of Medical Genetics and Genomics secondary findings recommendations (ACMG SF version 3.2). This designation reflects the gene's status as medically actionable when pathogenic variants are discovered incidentally during broader genomic sequencing. The actionability classification recognises that identifying CALM3 variants enables preventive interventions, such as avoidance of QT-prolonging medications, lifestyle modifications, and consideration of implantable cardioverter-defibrillators in high-risk individuals.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with pathogenic CALM3 variants, certain lifestyle considerations may help reduce the risk of cardiac arrhythmia episodes, though these should always be discussed with a cardiac specialist. Research in long QT syndrome and catecholaminergic polymorphic ventricular tachycardia suggests that avoiding known triggers can be beneficial as part of a comprehensive management strategy.
Physical exertion, particularly intense competitive sports or sudden bursts of activity, may trigger arrhythmias in some individuals with calmodulin-related cardiac conditions. Clinical guidelines for inherited arrhythmia syndromes generally recommend that affected individuals discuss appropriate levels of physical activity with their cardiology team. Whilst complete activity restriction is not typically necessary for all patients, understanding personal triggers and avoiding high-risk scenarios may form part of an individualised management plan.
Emotional stress and sudden loud noises have been reported as triggers for arrhythmic events, particularly in catecholaminergic polymorphic ventricular tachycardia. Maintaining regular sleep patterns and managing stress through appropriate techniques may be helpful, though no specific studies have quantified the protective benefit of such measures in this population. Some medications, particularly those that prolong the QT interval, can exacerbate arrhythmia risk and should be carefully reviewed with healthcare providers.
Electrolyte balance, particularly potassium and magnesium levels, can influence cardiac electrical activity in the general population. Maintaining adequate hydration and avoiding severe electrolyte depletion through balanced nutrition may support overall cardiac health, though specific dietary interventions have not been proven to prevent arrhythmias in individuals with CALM3 variants. Any lifestyle modifications should be undertaken as part of a comprehensive care plan developed with specialist cardiac input.
Supplement considerations
There is no conclusive evidence that any dietary supplement can prevent cardiac arrhythmias in individuals with pathogenic CALM3 variants. The cardiac conditions associated with CALM3 result from fundamental defects in calcium signalling and ion channel regulation that cannot be corrected through nutritional supplementation.
Some clinicians monitor and optimise magnesium and potassium levels in patients with long QT syndrome, as these electrolytes influence cardiac repolarisation. However, supplementation should only be undertaken with medical supervision, as excessive intake can cause harm. Self-directed supplementation with minerals or other compounds is not recommended and cannot substitute for evidence-based medical management.
Various supplements have been marketed for general cardiovascular health, but none have been validated specifically for preventing arrhythmias in genetic cardiac conditions. Some supplements may interact with antiarrhythmic medications or other treatments that individuals with CALM3 variants might be taking. For this reason, anyone considering taking supplements should discuss this with their healthcare provider to avoid potential interactions or adverse effects.
The cornerstone of management for calmodulin-related arrhythmias involves appropriate medical therapy, device therapy when indicated, and lifestyle modifications as recommended by cardiology specialists. Individuals with confirmed CALM3 variants should work closely with their cardiac team to develop an evidence-based treatment plan rather than relying on unproven supplements.
Frequently asked questions
What is the difference between CALM1, CALM2, and CALM3?
CALM1, CALM2, and CALM3 are three separate genes located on different chromosomes (14, 2, and 19 respectively) that all encode the exact same calmodulin protein. Despite having different DNA sequences in non-coding regions, they produce proteins with identical amino acid sequences. Pathogenic variants in any of the three genes can cause similar cardiac arrhythmia syndromes.
How common are CALM3 variants?
Pathogenic CALM3 variants are rare in the general population. The calmodulinopathies collectively represent a small proportion of inherited cardiac arrhythmia cases. Most individuals with long QT syndrome or catecholaminergic polymorphic ventricular tachycardia have variants in other genes, making CALM3-related disease uncommon even within these patient populations.
Can CALM3 variants affect organs other than the heart?
Whilst calmodulin is expressed throughout the body and participates in many cellular processes, the predominant clinical manifestations of pathogenic CALM3 variants involve the heart. Cardiac tissue appears particularly sensitive to calmodulin dysfunction, likely because precise calcium handling and ion channel regulation are essential for maintaining normal heart rhythm. Most reported cases focus on cardiac phenotypes.
Do all people with a CALM3 variant develop symptoms?
Most individuals with pathogenic CALM3 variants will develop some cardiac manifestations, though the age of onset and severity can vary. Some variants may have higher penetrance than others. The arrhythmias associated with CALM3 variants often present in childhood or adolescence, but the specific clinical course depends on the particular variant and individual factors.
How are CALM3-related cardiac conditions managed?
Management typically involves a combination of approaches tailored to the individual, which may include beta-blocker medications, lifestyle modifications to avoid triggers, and in some cases implantable cardioverter-defibrillators. Left cardiac sympathetic denervation surgery has been used in selected cases. Treatment decisions are made by specialist cardiac teams based on arrhythmia severity, symptoms, and individual risk factors.
Should family members of someone with a CALM3 variant be tested?
Cascade genetic testing is typically recommended for first-degree relatives of individuals with a pathogenic CALM3 variant, given the autosomal dominant inheritance pattern and the serious nature of the associated cardiac conditions. Identifying at-risk family members enables early surveillance and preventive measures. Such testing should be arranged through clinical genetics services with appropriate counselling.